Infection, Immunity & Global Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
Nat Commun. 2024 Aug 14;15(1):6968. doi: 10.1038/s41467-024-51413-7.
The use of pneumococcal conjugate vaccine (PCV) schedules with fewer doses are being considered to reduce costs and improve access, particularly in low- and middle-income countries. While several studies have assessed their immunogenicity, there are limited data on their potential for long-term immune protection, as assessed by pneumococcal serotype-specific memory B cell (B) responses. This current study reports secondary outcome data that aims to compare B responses following reduced-dose (0 + 1 and 1 + 1) schedules of PCV10 and PCV13 in Vietnamese infants from our randomised-controlled trial (trial registration number NCT03098628). Following vaccination at 12 months of age, B levels for most serotypes peaked seven days post-vaccination and were higher in magnitude for the 1 + 1 than 0 + 1 schedules and for PCV13 than PCV10. Furthermore, B did not wane as rapidly as IgG levels by 24 months of age. Further studies are needed to assess the use of B as markers of long-term protection against pneumococcal carriage and disease, which is crucial to generate data for immunisation program decision-making.
使用剂量较少的肺炎球菌结合疫苗（PCV）方案正被考虑用于降低成本和改善可及性，特别是在低收入和中等收入国家。虽然有几项研究评估了其免疫原性，但关于其通过肺炎球菌血清型特异性记忆 B 细胞（B）反应产生长期免疫保护的潜力的数据有限。本研究报告了次要结果数据，旨在比较我们的随机对照试验（试验注册号 NCT03098628）中越南婴儿接受 PCV10 和 PCV13 减毒（0+1 和 1+1）方案后的 B 反应。在 12 个月大时接种疫苗后，大多数血清型的 B 水平在接种后 7 天达到峰值，1+1 方案比 0+1 方案和 PCV13 比 PCV10 的幅度更高。此外，到 24 个月大时，B 不像 IgG 水平那样迅速下降。需要进一步研究来评估 B 作为预防肺炎球菌定植和疾病的长期保护的标志物的使用，这对于为免疫规划决策生成数据至关重要。
